Sysmex Corporation, headquartered in Kobe, Japan, is a prominent developer, manufacturer, and distributor of diagnostic instruments, reagents, and specialized software. The company's extensive offerings cater to diverse medical needs, including hematology, where it provides three-part and five-part white blood cell differentiation instruments, alongside high-volume testing transport systems for laboratories. In urinalysis, Sysmex offers advanced systems for analyzing formed sediment. Its immunochemistry portfolio includes automated systems capable of performing assays on minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Furthermore, the company develops flow cytometers essential for diagnosing critical conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Within the oncology space, Sysmex provides systems for identifying cancer lymph node metastasis and offers cancer genome profiling solutions, in addition to cytogenetic testing and laboratory assay services. The company is also deeply involved in digital medicine, creating and maintaining IT solutions, platforms, and applications for diagnostic information systems. Its broader activities encompass the development and sale of nucleic acid analogs, the marketing, design, manufacture, and after-sales support of medical robots, and the distribution of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Sysmex serves a wide array of medical institutions globally, from national and private hospitals to universities and research institutes, exporting its products to approximately 190 countries. The company has forged a strategic alliance with QIAGEN N.V. to develop and commercialize cancer companion diagnostics utilizing Plasma-Safe-SeqS technology. Established in 1968, the company was initially known as TOA Medical Electronics Co., Ltd. before adopting the Sysmex Corporation name in October 1998.